GeneCradle Inc
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO67%
Delay Index: of 6 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →
Open GeneCradle Inc on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GC301 NCT05793307 |
P1/2 | Active, not recruiting | Pompe Disease Infantile-Onset | 16 | 2025-12-31 (+13 mo) |
| GC301 NCT06391736 |
P1/2 | Recruiting | Pompe Disease (Late-onset) | 33 | 2026-12 |
| GC101 NCT05824169 |
P1/2 | Recruiting | Spinal Muscular Atrophy | 18 | 2026-12 (+12 mo) |
| GC101 adeno-associated virus injection NCT06971094 |
P3 | Active, not recruiting | SMA - Spinal Muscular Atrophy | 50 | 2026-12-31 |
| GC310 NCT07173933 |
P1/2 | Recruiting | Wilson Disease | 15 | 2027-12 (+8 mo) |
| GC101 NCT06421831 |
P1/2 | Recruiting | Spinal Muscular Atrophy Type 3 | 21 | 2027-12 (+12 mo) |